TVAMP
ALNY icon

Tennessee Valley Asset Management Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Tennessee Valley Asset Management Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-40
Closed -$7.66K – 147
2023
Q4 		$7.66K Buy
+40
New +$6.81K ﹤0.01% 495

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Tennessee Valley Asset Management Partners's ALNY Position: Q1 2024 in Review

Tennessee Valley Asset Management Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2024, closing a stake of 40 shares — an estimated $7.66K sold.

Tennessee Valley Asset Management Partners first reported a position in ALNY in Q4 2023 and held it in 1 quarter. The position peaked at $7.66K in Q4 2023. 499 funds tracked by Wall St. Rank hold ALNY as of Q1 2024.

  • Tennessee Valley Asset Management Partners reported no remaining Alnylam Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Tennessee Valley Asset Management Partners sold 40 Alnylam Pharmaceuticals shares in Q1 2024, an estimated $7.66K.
  • Tennessee Valley Asset Management Partners first reported a position in Alnylam Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Tennessee Valley Asset Management Partners's Alnylam Pharmaceuticals position peaked at $7.66K in Q4 2023.
  • 499 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2024.

Based on Tennessee Valley Asset Management Partners's 13F filing for Q1 2024, filed 23 Apr 2024.